Key Insights

Highlights

Success Rate

71% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

15.2%

5 terminated out of 33 trials

Success Rate

70.6%

-15.9% vs benchmark

Late-Stage Pipeline

9%

3 trials in Phase 3/4

Results Transparency

33%

4 of 12 completed with results

Key Signals

4 with results71% success

Data Visualizations

Phase Distribution

21Total
Not Applicable (9)
Early P 1 (1)
P 1 (3)
P 2 (5)
P 3 (3)

Trial Status

Completed12
Unknown6
Recruiting6
Terminated5
Active Not Recruiting1
Withdrawn1

Trial Success Rate

70.6%

Benchmark: 86.5%

Based on 12 completed trials

Clinical Trials (33)

Showing 20 of 20 trials
NCT06970262Not ApplicableNot Yet RecruitingPrimary

FMT for Lung and Associated-organ Rescue Efficacy in MDRO-infected Ventilated Patients

NCT05616221Phase 2Completed

Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection

NCT03236987Phase 3RecruitingPrimary

CLArithromycin Versus AZIthromycin in the Treatment of Mycobacterium Avium Complex (MAC) Lung Infections

NCT05620329Recruiting

UNC Pleural Fluid Registry

NCT07191080Enrolling By InvitationPrimary

Next-generation Sequencing Technology in the Clinical Application of Respiratory Specimens

NCT04467840Phase 2Completed

Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia

NCT05752019Completed

TAAI Erasmus Research Initiative to Fight CF: Monitoring Inflammation in CF Lung Disease Into a New Era

NCT06528418Recruiting

Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath

NCT05973201Not ApplicableRecruiting

Evaluation of Virtual Reality to Reduce Anxiety, Pain and Duration of Non-emergency Vigile Bronchial Fibroscopy (AVATAR)

NCT06648317Recruiting

Radiolabelled Nectin-4 Targeted LMW Probe PET/CT in Patients With Lung Lesions

NCT06106789Active Not Recruiting

A Study of the Clinical Benefit of Tobramycin Inhalation Solution

NCT02748798Early Phase 1Terminated

Developing Optimal Parameters for Hyperpolarized Noble Gas and Inert Fluorinated Gas MRI of Lung Disorders

NCT05630443Not ApplicableRecruiting

Effects of Prone Position After Major Abdominal Surgery

NCT04596319Phase 1Completed

Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis

NCT03816956Phase 3CompletedPrimary

Adjunctive Therapy to Antibiotics in the Treatment of S. Aureus Ventilator-Associated Pneumonia With AR-301

NCT02710383Terminated

Biomarker for Cystic Fibrosis

NCT02173613Not ApplicableTerminatedPrimary

Reduction the Duration of Antibiotic Therapy in the Elderly (PROPAGE)

NCT05349305Unknown

Population Pharmacokinetics of Lassila Tazobactam in Patients After Aortic Dissection

NCT04591158Not ApplicableCompleted

COVID-19 and Lung Ultrasound Utility

NCT04741217Unknown

Aerosolisation During Respiratory Procedures

Scroll to load more

Research Network

Activity Timeline